NIMR - Mbeya Medical Research Programme

Quick Information

NIMR - Mbeya Medical
Research Center

P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel    +255 25 250 3364
Fax   +255 25 250 3134
Working hours:
Mon   -  Fri
08:00 - 16:30 EAT (GMT + 3)

RV 262

“A Phase I Study of the Safety and Immunogenicity of PENNVAX™-G DNA (Env & Gag) Administered by Intramuscular Biojector® 2000 or by CELLECTRA® Intramuscular Electroporation Device Followed by MVA-CMDR (HIV-1 CM235 env/ CM240 gag/pol) Boost in Healthy, HIV Uninfected Adults”.

Team
Leonard Maboko (Principal Investigator), Arne Kroidl, Philip Mann, Bahati Kaluwa (Clinical Research Coordinator)

Purpose

RV262 is a phase I HIV vaccine trial to evaluate the safety and tolerability of the DNA vaccine candidates administered either by IM Biojector® 2000 injection or IM CELLECTRA® Electroporation followed by an IM MVA vector boost in healthy HIV-uninfected adult participants. The secondary objective is to evaluate the ability of the DNA/MVA prime/boost strategy to induce HIV antigen specific cellular and humoral immune responses.

Approach

The study consists of two parts:

Part A is an open-label, safety and tolerability study to be conducted at one clinical site at the Rockville Vaccine Assessment Clinic (RVAC), USA in 12 healthy, HIV-uninfected adult volunteers. Participants are randomized 1:1 to either the Biojector of the Electroporation delivery group. This part started in October 2010.

Part B is a randomized, placebo-controlled, double blind study to start after the product has been assessed as safe and tolerable in Part A. Part B will be conducted at three East African sites in Kenya, Uganda and Mbeya, Tanzania as well as in one site in Thailand enrolling overall 80 healthy, HIV negative. Low risk volunteers. Participants will be randomized 4:1 to active study drug versus placebo. This part is expected to start in July 2011. The NIMR Mbeya Medical Research Center (MMRC) in Tanzania will participate in the trial enrolling 20 participants.
The vaccine candidates are the PENNVAX™-G DNA (HIV-1 env A, C and D, and consensus gag plasmids) and MVA-CMDR Live attenuated Modified Vaccinia Ankara vector expressing HIV-1 CM235 env/ CM240 gag/pol. PENNVAX™-G DNA priming will be performed at months 0 and 1, MVA-CMDR boosting at months 3 and 6 of the vaccination schedule.

The Biojector® 2000 needle-free injection device delivers the study agent under pressure through a micro-orifice at high velocity using a compressed carbon dioxide cartridge.

Electroporation (EP) uses a needle to deliver the study agent intramuscular associated with short electric impulses. This delivery method is thought to increase the transfection of DNA into antigen-presenting cells (APCs) by creating transient pores in the cell membranes as well as to create mild tissue damage recruiting APCs locally and initiate an inflammatory response thus creating an adjuvant effect.

Sponsor

U.S. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH)

Partners

The trial will be lead by the Walter Reed Army Institute of Research (WRAIR) and the U.S. Military HIV Research Program (MHRP). The study site partners are the:

U.S. Army Medical Research Unit-Kenya and Kenya Medical Research Institute in Kericho, Kenya

Makerere University-Walter Reed Project in Kampala,Uganda,

NIMR-Mbeya Medical Research Center (MMRC) in Mbeya,Tanzania

Armed Forces Research Institute of Medical Services (AFRIMS) in Bangkok, Thailand

The LMU Department of Infectious Diseases and Tropical Medicine participate in this trial providing study coordination and management of the laboratory and immunology services. Logistical support is provided through the Munich office within the NIMR-MMRC collaboration.